Paeds Vivas · genetics-dysmorphology-and-metabolism
Klinefelter syndrome and sex chromosome aneuploidy — branching viva
Branching viva on Klinefelter syndrome and sex chromosome aneuploidy: recognising the clinical pattern across the lifespan, the extra-X gene-dosage model and X-inactivation escape genes, the endocrine trajectory and testosterone replacement, the neurodevelopmental and psychosocial phenotype, the prenatal counselling cascade, and the lifespan surveillance framework.
On this page & tools
Target exams
Opening question
A tall, shy fourteen-year-old boy is referred because he has not started puberty. On examination his testicular volume is 4 mL bilaterally — small and firm — and he has mild gynaecomastia and a history of language delay and learning difficulties. How do you confirm the diagnosis, and why is the karyotype essential rather than a microarray alone? [1] [2]
Branch 1 — the mechanism and the endocrine trajectory
Explain the extra-X gene-dosage model and the role of X-inactivation escape genes in producing the phenotype. Now describe the endocrine investigation profile you expect — LH, FSH, testosterone, inhibin B — and explain the pathophysiology of the progressive seminiferous tubule hyalinisation and Leydig cell dysfunction. When and how do you initiate testosterone replacement? [2] [3]
Branch 2 — the thromboembolism and metabolic risk
Fast forward to age twenty-five: the same patient presents with a deep vein thrombosis. What is the association between Klinefelter syndrome and venous thromboembolism — the risk increase and the mechanism? What metabolic and cardiovascular complications should he be screened for, and what monitoring does testosterone replacement require for safety? [3] [4]
Branch 3 — the prenatal counselling cascade
A different family is referred for counselling after cell-free DNA screening flagged a sex chromosome aneuploidy. What are the key counselling messages — the limitations of cell-free DNA, the phenotype variability, the ascertainment bias in the postnatal literature, and the evidence from the prospective eXtraordinarY babies study? How do you frame the conversation in a balanced, non-directive, strengths-based way? [1] [3]
Closing — the lifespan framework
In one sentence, what is the principle of sex chromosome aneuploidy management across the lifespan, and why is the surveillance framework a checklist that moves with the person from childhood through adolescence and into adulthood rather than a single visit? [4] [1]
References
- [1]Groth KA, Skakkebæk A, Høst C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab, 2013.PMID 23118429
- [2]Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. Lancet, 2004.PMID 15262106
- [3]Kanakis GA, Nieschlag E. Klinefelter syndrome: more than hypogonadism. Metabolism, 2018.PMID 29382506
- [4]Gies I, Unuane D, Velkeniers B, De Schepper J. Management of Klinefelter syndrome during transition. Eur J Endocrinol, 2014.PMID 24801585